A team led by Professor Nicholas Barnes at the University of Birmingham has identified a drug target that could tame brain inflammation at its source. Published in the journal *Brain*, the study used slices of human brain tissue obtained during neurosurgery — a first-of-its-kind approach — to show that blocking a receptor called P2X7 significantly dials down neuroinflammation. The twist: drugs that block this receptor already exist, raising the prospect of repurposing them for Alzheimer's and beyond.
The study's standout feature is its material: instead of relying on mouse models, the researchers worked with live cultures of human brain cells and slices of human brain tissue removed during neurosurgery. Their focus was the P2X7 receptor, which triggers inflammatory signaling and drives the release of cytokines — key proteins that orchestrate inflammation. Neuroinflammation has long been linked to brain disease, but the field lacked an intervention target validated in actual human tissue.
When the team blocked P2X7 with a specific antagonist, the inflammatory response in human brain tissue fell significantly. "This exciting discovery marks a major step toward repurposing existing therapeutics to combat neuroinflammation at its source," Barnes said. "The identification of this receptor could have far-reaching implications for some of the most debilitating and widespread brain disorders such as Alzheimer's disease, Parkinson's and multiple sclerosis, or inflammation-linked psychiatric conditions like schizophrenia and depression."
The paper paints a wide potential beneficiary map: traumatic brain injury, Alzheimer's, Parkinson's and other neurodegenerative diseases — plus depression and psychosis, conditions increasingly understood to carry a neuroinflammatory component. One target, multiple pipelines: the storyline the pharmaceutical industry likes best.
More tantalizing than the target itself are the words "existing drug." Since P2X7 antagonists already exist, they could theoretically be evaluated for new uses without starting drug discovery from scratch — saving years and enormous cost. In a parallel development, a Washington University team reported last week that blocking the CXCR3 pathway in mice cut T-cell infiltration into the brain roughly in half and preserved more brain tissue — two independent lines of work converging on neuroinflammation.
Caveats apply: the P2X7 evidence so far comes from tissue and cell cultures. Whether antagonists can safely cross the blood-brain barrier, work in a living human brain, and avoid side effects from long-term blockade remain open questions. Animal studies and early human trials come next. The direction is lit; the road still has to be walked step by step.